MIST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	38 074.00
Average Volume	323 677
Market Cap	88.23M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $-0.260 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.190
ATR14	$0.0190 (1.14%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-07	Wills Robert James	Buy	30 000	Stock Option (right to buy)
2023-06-07	Tomsicek Michael John	Buy	30 000	Stock Option (right to buy)
2023-06-07	Pasternak Richard C	Buy	30 000	Stock Option (right to buy)
2023-06-07	Liebert Debra K.	Buy	30 000	Stock Option (right to buy)
2023-06-07	Giles Lisa M.	Buy	30 000	Stock Option (right to buy)

INSIDER POWER
2.19
Last 95 transactions
Buy: 18 033 611 \| Sell: 4 881 578

Volume Correlation

Long: -0.04 (neutral)

Short: -0.05 (neutral)

Signal:(44.283) Neutral

Milestone Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Milestone Pharmaceuticals Correlation - Currency/Commodity

-0.09
( neutral )

-0.31
( neutral )

0.00
( neutral )

0.16
( neutral )

Milestone Pharmaceuticals Financials

Annual	2023
Revenue:	$1.00M
Gross Profit:	$402 000 (40.20 %)
EPS:	$-1.390

Q4	2023
Revenue:	$0
Gross Profit:	$-532 000 (0.00 %)
EPS:	$-0.410

Q3	2023
Revenue:	$0
Gross Profit:	$-23 999.00 (0.00 %)
EPS:	$-0.350

Q2	2023
Revenue:	$0
Gross Profit:	$-24 000.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.